Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INOVATYON phase III trial of trabectedin + PLD versus carboplatin + PLD in partially platinum-sensitive relapsed ovarian cancer
NL-OMON40022Phase 3Active, not recruiting
- Sponsor
- Mango
- Start
- Oct 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Carboplatin + PLD with Trabectedin + PLD (2 arms). Primary endpoint: Overall survival. Started Oct 2014; status: active, not recruiting.
02
Drugs
trabectedindoxorubicincarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON40022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40022.